Durable Clinical Benefit of Pertuzumab in a Young Patient with BRCA2 Mutation and HER2-Overexpressing Breast Cancer Involving the Brain

<div>Brain computed tomography at baseline (a) and after 3 (b), 9 (c), and 12 (d) months of treatment with pertuzumab, trastuzumab, and taxane-based chemotherapy.</div>

Case Reports in Oncological Medicine

fig2

Figure 2

Figure 2: Durable Clinical Benefit of Pertuzumab in a Young Patient with BRCA2 Mutation and HER2-Overexpressing Breast Cancer Involving the Brain 